Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma

• Liezel L. Griffin, MBBS,
• Laura Cove-Smith, PhD,
• Hana Alachkar, MD,
• John A. Radford, MD,
• Rebecca Brooke, MD,
• Kim M. Linton, PhD

Affiliations

Liezel L. Griffin, MBBS

Dermatology Centre, Salford Royal NHS Foundation Trust, Salford, United Kingdom

Laura Cove-Smith, PhD

Manchester Academic Health Sciences Centre, University of Manchester, Manchester, United Kingdom; Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom

Hana Alachkar, MD

Department of Immunology, Salford Royal NHS Foundation Trust, Salford, United Kingdom

John A. Radford, MD

Manchester Academic Health Sciences Centre, University of Manchester, Manchester, United Kingdom; Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom

Rebecca Brooke, MD

Dermatology Centre, Salford Royal NHS Foundation Trust, Salford, United Kingdom

Kim M. Linton, PhD

Manchester Academic Health Sciences Centre, University of Manchester, Manchester, United Kingdom; Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom; Correspondence to: Kim M. Linton, PhD, Senior Lecturer and Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, United Kingdom.